ClinicalTrials.gg
RecruitingNCT07851623Updated Oct 13, 2026

Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and Adults With Asthma

A Phase 1 interventional study of CHF10136 and CHF10136 matched placebo in Asthma and Healthy Volunteers, sponsored by Chiesi Farmaceutici S.p.A.. Recruiting at 3 sites in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Planned enrollment
29th of 66
120 · median 97
Started
2026
with 3 others
Phase 1
9 of 81
1 open now
Primary completion
2027-12
later than 7 of 10 live
Registered
80th of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 29th largest by planned enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2026, is one of 9 in phase 1, reaches primary completion later than 7 of the 10 other live ones, and was the 80th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

This study evaluates the safety and tolerability of CHF10136 administered by inhalation in healthy adults and adults with asthma. The study includes single-dose, multiple-dose, and repeated-dose treatment periods and will also characterize the pharmacokinetic profile of CHF10136.

Read the detailed description

This is a first-in-human (FiH), randomized, double-blind, placebo-controlled study of CHF10136 administered via dry powder inhaler.

The study consists of three sequential parts. Part 1 is a single ascending dose evaluation in healthy adult participants. Part 2 is a multiple ascending dose evaluation in participants with mild asthma. Part 3 is a repeated-dose evaluation in participants with moderate-to-severe asthma. Dose escalation and progression between study parts will occur following review of available safety and pharmacokinetic data.

Healthy participants and participants with asthma will be enrolled and randomized to receive CHF10136 or placebo. Safety assessments, pharmacokinetic sampling, and exploratory pharmacodynamic assessments will be performed throughout the study.

03

Conditions studied

  • Asthma
  • Healthy Volunteers

Browse trials for

Keywords

  • Asthma
  • First in Human
  • Adults
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For PART 1 - SAD

  • Healthy male or female participant ≥18 and ≤55 years of age
  • (BMI) ≥18 and ≤30 kg/m2 at screening and weight at least 50 kg;
  • Good physical and mental status, determined via assessment of medical history at screening and physical examination at screening and prior to randomisation;
  • Spirometry measurements within normal limits at screening and prior to randomisation based on the American Thoracic Society (ATS)/European Respiratory Society (ERS) interpretative strategies for spirometry. The (FEV1) must be >80% of predicted normal value and the FEV1/Forced Vital Capacity (FVC) ratio must be >0.7.
  • Male and Female participants willing and able to comply with study procedures

For PART 2 - MAD

  • Male or female participants ≥18 and ≤55 years of age at screening
  • BMI ≥18 and ≤32 kg/m2 at screening and weight at least 50 kg;
  • Physician-diagnosed asthma for at least 6 months and before the age of 50 years. Documented evidence of one of the confirmed variable expiratory airflow criteria, as per the GINA 2026 guidelines, is required within 10 years prior to screening.
  • Not currently receiving regular maintenance therapy for asthma, with no changes to treatment within \<4 weeks prior to screening, and no exposure to ICS in the 12 weeks prior to screening including ICS reliever therapy;
  • Pre-bronchodilator FEV1 ≥70% of predicted at the screening visit and prior to randomisation;
  • Male and Female participants willing and able to comply with study procedures

For PART 3 - REPEATED DOSE

  • Male or female participants ≥18 and ≤65 years of age at screening
  • BMI ≥18 and ≤35 kg/m2 at screening and weight at least 50 kg;
  • Physician-diagnosed asthma for at least 6 months and before the age of 50 years. Documented evidence of one of the confirmed variable expiratory airflow criteria, as per the GINA 2026 guidelines, is required within 10 years prior to screening.
  • On a stable asthma treatment regimen of medium to high dose Inhaled /Long-Acting Beta2-Agonists(ICS/LABA) (as defined by GINA 2026 guidelines) with no changes to treatment within 12 weeks prior to screening.
  • Pre-bronchodilator FEV1 ≥40% and ≤90% of predicted at the screening visit and prior to randomisation;
  • Asthma Control Questionnaire - 6 Items (ACQ-6) score of 0.5 to 3.0 at screening and prior to randomisation;
  • Male and Female participants willing and able to comply with study procedures

Exclusion criteria

EXCLUSION CRITERIA:

For PART 1 - SAD

  • Participation in another clinical study where drug was received less than 90 days or 5 half-lives prior to screening, whichever is longer;
  • respiratory, cardiac, hepatic, gastrointestinal, renal, endocrine, haematologic, metabolic, neurological or psychiatric disorders that may interfere with successful completion of this protocol, according to the Investigator's judgment;
  • Clinically relevant abnormal laboratory values at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the participant or the evaluation of the results of the study, according to the Investigator's judgment.
  • Positive hepatitis panel and/or positive test at the screening visit.
  • Presence of any current infection, previous infection that resolved less than 7 days prior to screening or prior to randomisation or other latent or chronic infections (e.g. recurrent sinusitis, genital or ocular herpes, urinary tract infection);
  • History of within 5 years of screening (non-melanoma skin cancer is permitted if adequately treated for 12 months prior to screening);
  • Abnormal liver enzymes at screening or prior to randomisation ( [ALT] or aspartate aminotransferase [AST] or total : >1.0 × [ULN]).
  • Known intolerance and/or to the Investigational Medicinal Product (IMP) or to any of the contained in the formulation used in the study;
  • For females only: pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until termination of the gestation.

For PART 2 - MAD

  • Participation in another clinical study where investigational drug was received less than 90 days or 5 half-lives prior to screening, whichever is longer;
  • Clinically relevant and uncontrolled respiratory disorders, including high-risk and non-persistent asthma; clinically relevant, uncontrolled, cardiac, hepatic, gastrointestinal, renal, endocrine, haematologic, metabolic, neurological or psychiatric disorders that may interfere with successful completion of this protocol, according to the Investigator's judgment;
  • History of any clinically significant respiratory disorders including but not limited to , idiopathic pulmonary fibrosis, alpha-1 antitrypsin deficiency, bronchiectasis, sarcoidosis, pulmonary hypertension or interstitial lung disease;
  • Clinically relevant abnormal laboratory values at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the participant or the evaluation of the results of the study, according to the Investigator's judgment.
  • Positive hepatitis panel and/or positive HIV test at the screening visit.
  • Presence of any current infection, previous infection that resolved less than 7 days prior to screening or prior to randomisation or other latent or chronic infections (e.g. recurrent sinusitis, genital or ocular herpes, urinary tract infection);
  • Lower respiratory tract infection not resolved within 8 weeks prior to screening and/or randomisation, as determined by the Investigator;
  • Asthma exacerbation requiring medication or visit to the emergency department, including increase in Short-Acting Beta-Agonists (SABA) use, within 8 weeks of screening or during the study;
  • Use of inhaled or systemic within 12 weeks of screening or prior to randomisation;
  • Use of any asthma controller medication within 4 weeks of screening or prior to randomisation (including, but not limited to, LABA, leukotriene antagonists, xanthines, anti-cholinergics);
  • History of malignancy within 5 years of screening (non-melanoma skin cancer is permitted if adequately treated for 12 months prior to screening);
  • Abnormal liver enzymes at screening or prior to randomisation (ALT or AST or total bilirubin:>1.0 × upper limit of normal [ULN]).
  • For females only: pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until termination of the gestation.

For PART 3 - REPEATED DOSE

  • Participation in another clinical study where investigational drug was received less than 90 days or 5 half-lives prior to screening, whichever is longer;
  • Clinically relevant and uncontrolled respiratory disorders, including high-risk and non-persistent asthma; clinically relevant, uncontrolled, cardiac, hepatic, gastrointestinal, renal, endocrine, haematologic, metabolic, neurological or psychiatric disorders that may interfere with successful completion of this protocol, according to the Investigator's judgment;
  • History of any clinically significant respiratory disorders including but not limited to chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, alpha-1 antitrypsin deficiency, bronchiectasis, sarcoidosis, pulmonary hypertension or interstitial lung disease;
  • Clinically relevant abnormal laboratory values at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the participant or the evaluation of the results of the study, according to the Investigator's judgment.
  • Positive hepatitis panel and/or positive HIV test at the screening visit.
  • Presence of any current infection, previous infection that resolved less than 7 days prior to screening or prior to randomisation or other latent or chronic infections (e.g. recurrent sinusitis, genital or ocular herpes, urinary tract infection);
  • Asthma exacerbation or lower respiratory tract infection requiring medication or visit to the emergency department within 4 weeks prior to screening and/or prior to randomisation;
  • Use of systemic corticosteroids within 8 weeks of screening or prior to randomisation;
  • History of malignancy within 5 years of screening;
  • For females only: pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until termination of the gestation;
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    CHF10136.

    Participants receive CHF10136 administered via dry powder inhaler. Doses vary according to study cohort.

    Drug: CHF10136

  • Placebo comparator
    Placebo

    Participants receive placebo powder for inhalation administered via dry powder inhaler.

    Drug: CHF10136 matched placebo

Interventions

  • DrugCHF10136

    CHF10136 powder for inhalation administered orally using a Dry Powder Inhaler.

  • DrugCHF10136 matched placebo

    Matching placebo powder for inhalation administered using a Dry Powder Inhaler.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    Assessment of safety through collection of treatment-emergent adverse events.

    Time frame: Part 1, 2 and 3: Day - 28 to Day - 2 (Screening Visit), Day -1, Day 1, Day 2, Day 3, Day 4, and Day 8 (Follow-up Visit)

  2. Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure

    Time frame: Part 1, 2 and 3:Day - 28 to Day - 2 (Screening Visit), Day -1, Day 1, Day 2, Day 3, Day 4, and Day 8 (Follow-up Visit)

  3. Change From Baseline in Electrocardiogram Parameters: HR (Heart Rate)

    Time frame: Part 1, 2 and 3:Day - 28 to Day - 2 (Screening Visit), Day -1, Day 1, Day 2, Day 3, Day 4, and Day 8 (Follow-up Visit)

  4. Change From Baseline in Electrocardiogram Parameters: Intervals recorded: PR, QT, QRS duration, QTcF (Fridericia corrected QT interval)

    Time frame: Part 1: Day 1 to Day 2 - Part 2 & 3: Day 1 to Day N + 1 (Day after the last treatment intake)

  5. Change From Baseline in Clinical Laboratory Parameters

    Number of subjects with abnormal blood laboratory test results. Quantitative laboratory parameters (chemistry and haematology) will be summarised by treatment as absolute value and change from baseline using descriptive statistics. Number of subjects with abnormal urine laboratory test results.

    Time frame: Part 1: Screening visit, Day -1, Day 4 and Day 8 - Part 2 & 3: Screening Visit, Day -1, Day 4 , Day 7, Day N+1 (Day after the last treatment intake), Day N+7 (Follow-up Visit)

  6. Change From Baseline in Forced Expiratory Volume in One Second (FEV1)

    Time frame: Part 1: Screening Visit, Day 1 and Day 2 - Part 2& 3: Screening Visit, Day -1, Day 1 and Day N (the last day of treatment intake)

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve (AUC) for CHF10136 (parent compound) and its main metabolite.)

    Time frame: Part 1: Up to 72 hours post-dose and on Day 1 - Part 2 & 3: Day N (the last day of treatment intake )

  2. Maximum Observed Plasma Concentration (Cmax) of CHF10136 (parent compound) and its main metabolite.)

    Time frame: Part 1: on Day 1, up to 72 hours post-dose - Part 2 & 3: on Day 1 and Day N (the last day of treatment intake )

  3. Time to Maximum Plasma Concentration (Tmax) of CHF10136 (parent compound) and its main metabolite.)

    Time frame: Part 1: on Day 1, up to 72 hours post-dose - Part 2 & 3: on Day 1 and Day N (the last day of treatment intake )

  4. Terminal Half-Life (t½) of CHF10136 (parent compound) and its main metabolite.)

    Time frame: Day 1 for Part 1

  5. Apparent Clearance (CL/F) of CHF10136 (parent compound) and its main metabolite.)

    Time frame: Up to 72 hours post-dose

  6. Apparent Volume of Distribution (Vz/F) of CHF10136 (parent compound) and its main metabolite.)

    Time frame: Up to 72 hours post-dose

  7. Pharmacokinetic Parameters of the main Metabolite

    includes AUC

    Time frame: Up to 72 hours post-dose

  8. Pharmacokinetic Parameters of the main Metabolite

    includes Cmax

    Time frame: Up to 72 hours post-dose

  9. Pharmacokinetic Parameters of the main Metabolite

    include Metabolite Ratios

    Time frame: Up to 72 hours post-dose

07

Study locations

1 of 3 sites recruiting
  • Fortrea Leeds CRU
    Leeds, United Kingdom
    Recruiting
  • hVIVO
    London, United Kingdom
    Not yet recruiting
  • MEU
    Manchester, United Kingdom
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No — Chiesi clinical data sharing scope, process and data access criteria is available on the Chiesi Group website

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 14 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Oct 1, 2026
StartActual
Oct 2, 2026
Primary completionEst.
Dec 27, 2027
CompletionEst.
Dec 27, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
Show 3 sites
  • Fortrea Leeds CRU · Leeds, United Kingdomno status→Recruiting
  • hVIVO · London, United Kingdomno status→Not yet recruiting
  • MEU · Manchester, United Kingdomno status→Not yet recruiting
Oct 13, 2026
Start date
Oct 1, 2026→Oct 2, 2026 (actual)
Oct 13, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
    Show 3 sites
    • Fortrea Leeds CRU · Leeds, United Kingdomno status→Recruiting
    • hVIVO · London, United Kingdomno status→Not yet recruiting
    • MEU · Manchester, United Kingdomno status→Not yet recruiting
    Start date Oct 1, 2026→Oct 2, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851623
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Oct 2, 2026
Primary completion
Dec 27, 2027 (estimated)
Completion
Dec 27, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Chiesi Clinical trial Info clinicaltrials_info@chiesi.com
Contact
clinicaltrials_info@chiesi.com
+390521279715
Rory Taylor, MD
study director · Chiesi Farmaceutici S.p.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion